View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsOrapi 배당 및 자사주 매입배당 기준 점검 0/6Orapi 현재 배당금을 지급하지 않습니다.핵심 정보0%배당 수익률-0.2%자사주 매입 수익률총 주주 수익률-0.2%미래 배당 수익률0%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향0%최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • Nov 01New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: €27m Forecast net loss in 1 year: €6.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (€6.5m net loss next year). Market cap is less than US$100m (€42.1m market cap, or US$45.6m).Buy Or Sell Opportunity • Apr 29Now 27% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.5% to €5.80. The fair value is estimated to be €7.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.3% over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • Apr 19Full year 2023 earnings released: €2.89 loss per share (vs €0.12 profit in FY 2022)Full year 2023 results: €2.89 loss per share (down from €0.12 profit in FY 2022). Revenue: €229.1m (flat on FY 2022). Net loss: €18.8m (down €19.6m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 138 percentage points per year, which is a significant difference in performance.New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (€8.8m net loss next year). Market cap is less than US$100m (€42.3m market cap, or US$45.9m).New Risk • Dec 08New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: €7.2m Forecast net loss in 1 year: €2.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (€2.5m net loss next year). Market cap is less than US$100m (€42.0m market cap, or US$45.3m).Valuation Update With 7 Day Price Move • Jun 13Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €4.30, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 12x in the Chemicals industry in Germany. Total loss to shareholders of 6.5% over the past year.Buying Opportunity • Oct 26Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 19%. The fair value is estimated to be €5.19, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 55% per annum over the same time period.Buying Opportunity • Oct 11Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be €5.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 54% per annum over the same time period.Buying Opportunity • Sep 17Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €5.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 52% per annum over the same time period.Reported Earnings • Apr 16Full year 2021 earnings released: EPS: €0.03 (vs €1.70 in FY 2020)Full year 2021 results: EPS: €0.03 (down from €1.70 in FY 2020). Revenue: €226.6m (down 15% from FY 2020). Net income: €195.0k (down 98% from FY 2020). Profit margin: 0.1% (down from 3.4% in FY 2020). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 4.6%, compared to a 11% growth forecast for the industry in Germany.Valuation Update With 7 Day Price Move • Mar 17Investor sentiment improved over the past weekAfter last week's 17% share price gain to €5.72, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 10x in the Chemicals industry in Germany. Total loss to shareholders of 43% over the past year.Reported Earnings • Sep 22First half 2021 earnings released: EPS €0.37 (vs €1.92 in 1H 2020)The company reported a poor first half result with weaker earnings, revenues and profit margins. First half 2021 results: Revenue: €117.6m (down 16% from 1H 2020). Net income: €2.46m (down 72% from 1H 2020). Profit margin: 2.1% (down from 6.3% in 1H 2020).Reported Earnings • Apr 17Full year 2020 earnings released: EPS €1.70 (vs €0.64 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €267.5m (up 11% from FY 2019). Net income: €9.22m (up €12.2m from FY 2019). Profit margin: 3.4% (up from net loss in FY 2019). The move to profitability was driven by higher revenue.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 O4P 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: O4P 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Orapi 배당 수익률 vs 시장O4P의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (O4P)0%시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.8%업계 평균 (Chemicals)3.9%분석가 예측 (O4P) (최대 3년)0%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 O4P 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 O4P 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: O4P German 시장에서 주목할만한 배당금을 지급하지 않습니다.주주 현금 배당현금 흐름 범위: O4P 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/12/22 13:00종가2024/12/11 00:00수익2024/06/30연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Orapi SA는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Stephanie LefebvreGilbert Dupont
New Risk • Nov 01New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: €27m Forecast net loss in 1 year: €6.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (€6.5m net loss next year). Market cap is less than US$100m (€42.1m market cap, or US$45.6m).
Buy Or Sell Opportunity • Apr 29Now 27% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.5% to €5.80. The fair value is estimated to be €7.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.3% over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • Apr 19Full year 2023 earnings released: €2.89 loss per share (vs €0.12 profit in FY 2022)Full year 2023 results: €2.89 loss per share (down from €0.12 profit in FY 2022). Revenue: €229.1m (flat on FY 2022). Net loss: €18.8m (down €19.6m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 138 percentage points per year, which is a significant difference in performance.
New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (€8.8m net loss next year). Market cap is less than US$100m (€42.3m market cap, or US$45.9m).
New Risk • Dec 08New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: €7.2m Forecast net loss in 1 year: €2.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (€2.5m net loss next year). Market cap is less than US$100m (€42.0m market cap, or US$45.3m).
Valuation Update With 7 Day Price Move • Jun 13Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €4.30, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 12x in the Chemicals industry in Germany. Total loss to shareholders of 6.5% over the past year.
Buying Opportunity • Oct 26Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 19%. The fair value is estimated to be €5.19, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 55% per annum over the same time period.
Buying Opportunity • Oct 11Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be €5.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 54% per annum over the same time period.
Buying Opportunity • Sep 17Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €5.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 52% per annum over the same time period.
Reported Earnings • Apr 16Full year 2021 earnings released: EPS: €0.03 (vs €1.70 in FY 2020)Full year 2021 results: EPS: €0.03 (down from €1.70 in FY 2020). Revenue: €226.6m (down 15% from FY 2020). Net income: €195.0k (down 98% from FY 2020). Profit margin: 0.1% (down from 3.4% in FY 2020). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 4.6%, compared to a 11% growth forecast for the industry in Germany.
Valuation Update With 7 Day Price Move • Mar 17Investor sentiment improved over the past weekAfter last week's 17% share price gain to €5.72, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 10x in the Chemicals industry in Germany. Total loss to shareholders of 43% over the past year.
Reported Earnings • Sep 22First half 2021 earnings released: EPS €0.37 (vs €1.92 in 1H 2020)The company reported a poor first half result with weaker earnings, revenues and profit margins. First half 2021 results: Revenue: €117.6m (down 16% from 1H 2020). Net income: €2.46m (down 72% from 1H 2020). Profit margin: 2.1% (down from 6.3% in 1H 2020).
Reported Earnings • Apr 17Full year 2020 earnings released: EPS €1.70 (vs €0.64 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €267.5m (up 11% from FY 2019). Net income: €9.22m (up €12.2m from FY 2019). Profit margin: 3.4% (up from net loss in FY 2019). The move to profitability was driven by higher revenue.